Mangoceuticals Inc. (MGRX)
NASDAQ: MGRXHealth CareMisc Health and Biotechnology ServicesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MGRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.75M
- EPS (TTM)
- -$0.52
- Dividend yield
- None
- 52-week range
- 0.121 – 1.38
- Day range
- 0.1213 – 0.1371
- Volume / Avg
- 241.10K / 638.90K
- Beta
- —
- Shares outstanding
- 22.22M
52-week range
MGRX stock today
Mangoceuticals (MGRX) closed at $0.1236 on Nov 20, down 7.55% (-$0.0101), versus the S&P 500's 3.70% decline. Trading was light, with 241.10K shares changing hands, about 38% of the average daily volume. At this level, MGRX sits near the bottom of its 52-week range of $0.121 to $1.38: 91.0% below the high and 2.1% above the low.
Mangoceuticals has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Mangoceuticals
Company profileMangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand.
- Sector
- Health Care
- Industry
- Misc Health and Biotechnology Services
- CEO
- Mr. Jacob D. Cohen
- Headquarters
- Dallas, TX
- Employees
- 3
- IPO year
- 2023
- Website
- mangoceuticals.com
Financial highlights
Full financialsIn fiscal 2025, Mangoceuticals generated $456,021 in revenue, down 26.0% from fiscal 2024, its first annual decline since 2024. Mangoceuticals reported a net loss of $20.6 million, compared with a loss of $8.7 million a year earlier. Gross margin was 54.9% (down from 61.7%) and operating margin -3954.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $456.02K | $615.87K | $731.49K | $8.94K |
| Growth | -25.96% | -15.81% | +8083.16% | — |
| Net income | $-20.64M | $-8.71M | $-9.21M | $-2.00M |
| EPS (diluted) | $-2.17 | $-4.80 | $-8.58 | $-0.19 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.18 vs —
MGRX news
All MGRX newsMangoceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NIVFNewGenIvf Group Limited Class A | 0.0269 | -23.14% | $80.77K | vs MGRX |
| CCELCryo-Cell International Inc. | 4.15 | 0.00% | $33.46M | vs MGRX |
| PARKPark Dental Partners Inc. | 17.03 | -6.79% | $94.26M | vs MGRX |
| VMDViemed Healthcare Inc. | 8.52 | -1.05% | $322.85M | vs MGRX |
| AGLagilon health inc. | 90.24 | +0.83% | $1.52B | vs MGRX |
| PGNYProgyny Inc. | 35.71 | +0.73% | $2.63B | vs MGRX |
| SHCSotera Health Company | 15.91 | -1.85% | $4.54B | vs MGRX |
| DVADaVita Inc. | 161.03 | +3.00% | $10.13B | vs MGRX |
Indexes, lists and sector
Mangoceuticals stock FAQ
What is Mangoceuticals's stock price today?
MGRX last traded at $0.1236 as of Nov 20, 4:00 PM EST, down 7.55% on the day. Prices are delayed at least 15 minutes.
Who is Mangoceuticals's CEO?
Mr. Jacob D. Cohen is the chief executive officer of Mangoceuticals Inc., which has about 3 employees.
What is the MGRX 52-week high?
The 52-week high for MGRX is $1.38 and the 52-week low is $0.121. The stock is currently 91.0% below its high.